New insights into pharmacological treatment for STEMI

Session comprising selected EuroPCR 2026 abstract submissions

Moderators: A. Greco, P. Steg

Speakers: B. Yosofi, N. Vythoulkas-Biotis, C. Laudani, P. Smits, P. Gupta, B. Hudzik

Summary

This session presents the latest pharmacological advances in the treatment of ST-segment elevation myocardial infarction (STEMI). It covers safety data on ticagrelor monotherapy post-primary PCI, the impact of P2Y12 inhibitor pretreatment, effects of dapagliflozin on myocardial remodeling, and considerations for bleeding risk and vascular preparation strategies to optimize STEMI patient outcomes.

Presentations available when logged in:

Safety of ticagrelor monotherapy after primary PCI for STEMI: outcomes at 13 months
Impact of P2Y12 pretreatment on clinical outcomes in patients with STEMI: a meta-analysis
Effects of Dapagliflozin on myocardial fibrosis and ventricular function in STEMI
Dyspnea with potent P2Y12 inhibitors after stenting in low risk myocardial infarction patients
Comparison of routine vs. need-based vascular bed preparation in patients undergoing primary PCI
Selecting high-bleeding risk AMI patients with atrial fibrillation for triple antithrombotic therapy after PCI

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

New insights into pharmacological treatment for STEMI

Session comprising selected EuroPCR 2026 abstract submissions

Log in or create account for free